|From: singhtelecom (Rep: 986) reply to hunter1||Date: 08/01/2020 10:23|
|Forum: Aileron Therapeutics Inc. - Msg #90||Thread #674114984 (Rec: 0) |
The rationale for evaluating this combination is supported by the synergistic activity observed in preclinical models; single-agent ALRN-6924 activity in MDM2-amplifed patients in earlier clinical trials; and the frequent co-amplification of MDM2 (the target of ALRN-6924) and CDK4 (the target of palbociclib) due to their co-localization on chromosome 12. Tumors with the highest frequency of MDM2 amplification include sarcomas, urothelial cancers, lung cancers, gliomas and a number of other tumor types. There are no approved therapies that specifically target tumors that are driven by MDM2 amplification or MDM2/CDK4 co-amplification, thereby creating an opportunity to develop ALRN-6924 in this patient population.
In early 2019, we commenced a Phase 2a trial to test the combination of ALRN-6924 and palbociclib in patients with MDM2-amplified tumors. This is a multicenter, non-randomized trial which enrolled 34 patients in the United States. The objectives of this trial include evaluation of safety, tolerability, and activity of the combination.
We reported interim results from our Phase 2a trial at the European Society for Medical Oncology (ESMO) Congress in Barcelona on the 28th of September 2019. View Poster
As of March 15, 2020, there were seven out of 34 patients still on treatment and we currently anticipate the final PFS analysis and presentation of the results from this Phase 2a trial in the second half of 2020.Re: Bio low floater trending up... keep on watch!
| Reply to hunter1 - Msg #77 - 01/06/2020 11:14|
Re: Bio low floater trending up... keep on watch!
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 2020- TheLion.com, Inc.